Gilead Sciences Announces Promotion of Alessandro Riva to Executive Vice President, Oncology Therapeutics
October 17 2017 - 8:30AM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today the
promotion of Alessandro Riva, MD, to Executive Vice President,
Oncology Therapeutics, with responsibility for Gilead’s hematology
and oncology programs, including cell therapy research and
development. Dr. Riva will become a member of Gilead’s senior
leadership team.
Dr. Riva joined Gilead in January 2017 as Senior Vice President,
Hematology and Oncology Therapeutic Area Head. He has been
instrumental in expanding Gilead’s oncology program with the recent
acquisition of Kite Pharma, establishing the company as a leader in
the field of cellular therapy. He has also guided the strategy and
development of Gilead’s broader oncology pipeline during his
tenure.
Prior to joining Gilead, Dr. Riva served as
Head, Global Oncology Development at Novartis, where he
oversaw the development and worldwide regulatory approval of
multiple compounds in a variety of tumor types. He received his
bachelor’s degree in Medicine and a Certificate Board in
Oncology/Hematology from the School of Medicine of Milan.
Earlier in his career, he worked as a physician, treating patients
with hematological malignancies at the University
Hospital of Milan.
“Alessandro’s vision and insight have helped Gilead broaden and
deepen our oncology pipeline through the acquisition of Kite
Pharma, and his exceptional leadership has guided the company’s
broader hematology/oncology strategy,” said John McHutchison, MD,
Executive Vice President, Clinical Research. “In his new role, I am
confident that Gilead’s hematology and oncology programs will
continue to expand, as we seek to advance new therapies with the
potential to transform the treatment of patients with cancer.”
About Gilead
Sciences
Gilead Sciences is a biopharmaceutical company that
discovers, develops and commercializes innovative therapeutics in
areas of unmet medical need. The company’s mission is to advance
the care of patients suffering from life-threatening diseases.
Gilead has operations in more than 30 countries worldwide, with
headquarters in Foster City, California.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. The reader is cautioned not to rely on these
forward-looking statements. These and other risks are described in
detail in Gilead’s Quarterly Report on Form 10-Q for the quarter
ended June 30, 2017, as filed with the U.S. Securities and
Exchange Commission. All forward-looking statements are based on
information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com, follow Gilead on
Twitter (@GileadSciences) or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171017005582/en/
Gilead Sciences, Inc.InvestorsSung Lee, 650-524-7792orMediaAmy
Flood, 650-522-5643
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024